PRE-EXPOSING CANADA GEESE (BRANTA CANADENSIS) TO A LOW-PATHOGENIC H1N1 AVIAN INFLUENZA VIRUS PROTECTS THEM AGAINST H5N1 HPAI VIRUS CHALLENGE

2014 ◽  
Vol 50 (1) ◽  
pp. 84-97 ◽  
Author(s):  
Yohannes Berhane ◽  
Carissa Embury-Hyatt ◽  
Marsha Leith ◽  
Helen Kehler ◽  
Matthew Suderman ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Branta Canadensis ◽  
Canada Geese ◽  
Virus Challenge ◽  
H5n1 Hpai

scholarly journals Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge

Virology ◽  
2009 ◽  
Vol 395 (2) ◽  
pp. 182-189 ◽  
Author(s):  
Ki Seok Park ◽  
Jiyeung Lee ◽  
So Shin Ahn ◽  
Young-Ho Byun ◽  
Baik Lin Seong ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Mucosal Immunity ◽  
Virus Challenge ◽  
H5n1 Hpai

Experimental infection of juvenile domestic and Canada geese with two different clades of H5N1 high pathogenicity avian influenza virus

2013 ◽  
Vol 163 (3-4) ◽  
pp. 235-241 ◽  
Author(s):  
K. Śmietanka ◽  
Z. Minta ◽  
M. Reichert ◽  
M. Olszewska ◽  
K. Wyrostek ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Experimental Infection ◽  
Canada Geese ◽  
High Pathogenicity

scholarly journals Bursopentine as a Novel Immunoadjuvant Enhances both Humoral and Cell-Mediated Immune Responses to Inactivated H9N2 Avian Influenza Virus in Chickens

2011 ◽  
Vol 18 (9) ◽  
pp. 1497-1502 ◽  
Author(s):  
Deyuan Li ◽  
Maoyun Xue ◽  
Chen Wang ◽  
Junbao Wang ◽  
Puyan Chen
Keyword(s):  
Immune Response ◽  
T Cells ◽  
Influenza Virus ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Interleukin 2 ◽  
Elevated Serum ◽  
Peripheral Blood Lymphocytes ◽  
Strong Immune Response ◽  
Virus Challenge

ABSTRACTThere is an urgent need for identification of a new adjuvant capable of selectively promoting an efficient immune response for use with vaccines and especially subunit vaccines. Our pervious study showed that Bursopentine (BP5) is a novel immunomodulatory peptide and has the ability to significantly stimulate an antigen-specific immune response in mice. In this study, the potential adjuvant activities of BP5 were examined in chickens by coinjection of BP5 and an inactivated avian influenza virus (AIV) (A/Duck/Jiangsu/NJ08/05 [AIV H9N2 subtype]). The results suggested that BP5 markedly elevated serum hemagglutination inhibition (HI) titers and antigen-specific antihemagglutinin (anti-HA) antibody (IgG) levels, induced both Th1 (interleukin 2 [IL-2] and gamma interferon [IFN-γ])- and Th2 (IL-4)-type cytokines, promoted the proliferation of peripheral blood lymphocytes, and increased populations of CD3+T cells and their subsets CD4+(CD3+CD4+) T cells and CD8+(CD3+CD8+) T cells. Furthermore, a virus challenge experiment revealed that BP5 contributes to protection against homologous avian influenza virus challenge by reducing viral replication in chicken lungs. This study indicates that the combination of inactivated AIVs and BP5 gives a strong immune response at both the humoral and cellular levels and implies that BP5 is a novel immunoadjuvant suitable for vaccine design.

scholarly journals Neuraminidase in Virus-Like Particles Contributes to the Protection against High Dose of Avian Influenza Virus Challenge Infection

Pathogens ◽  
2021 ◽  
Vol 10 (10) ◽  
pp. 1291
Author(s):  
Hae-Ji Kang ◽  
Ki-Back Chu ◽  
Keon-Woong Yoon ◽  
Gi-Deok Eom ◽  
Jie Mao ◽  
...  
Keyword(s):  
Influenza Virus ◽  
T Cell ◽  
Avian Influenza ◽  
Avian Influenza Virus ◽  
Critical Role ◽  
Protective Role ◽  
Challenge Infection ◽  
High Dose ◽  
Post Challenge ◽  
Virus Challenge

Neuraminidase is an important target for influenza vaccination. In this study, we generated avian influenza VLPs, expressing hemagglutinin (HA), neuraminidase (NA), HA and NA co-expressed (HANA), to evaluate the protective role of NA against a high (10LD50) and low (2LD50) dose of avian influenza virus challenge infections. A single immunization with HANA VLPs elicited the highest level of virus-specific IgG, IgG1, and IgG2a responses from the sera post-vaccination and the lungs post-challenge-infection. Potent antibody-secreting cell responses were observed from the spleens and lungs of HANA-VLP-immunized mice post-challenge-infection. HANA VLPs induced the highest CD4+ T cell, CD8+ T cell, and germinal center B cells, while strongly limiting inflammatory cytokine production in the lungs compared to other VLP immunization groups. In correlation with these findings, the lowest bodyweight losses and lung virus titers were observed from HANA VLP immunization, and all of the immunized mice survived irrespective of the challenge dose. Contrastingly, VLPs expressing either HA or NA alone failed to elicit complete protection. These results indicated that NA in VLPs played a critical role in inducing protection against a high dose of the challenge infection.

Sign in / Sign up

Export Citation Format

Share Document